DOT Seeks Input on Adding Fentanyl to Official Testing Panel: How Employers Should Prepare

What is new?

On September 2, 2025, the U.S. Department of Transportation officially published a Notice of Proposed Rulemaking (NPRM) to amend 49 CFR Part 40. The proposal would add fentanyl (urine + oral fluid) and norfentanyl (urine only) to the DOT drug testing panel, aligning with the updated HHS drug testing guidelines. The public comment window is open until October 17, 2025. (Federal Register, DOT)

Why It’s a Big Deal

Safety alignment & overdose crisis: DOT says adding fentanyl enhances workplace safety, particularly in transportation, by reflecting its rising role in overdose fatalities. (Land Line Media)
More than labels:The NPRM also proposes harmonizing DOT’s procedures with the latest HHS Mandatory Guidelines, including clarity around cutoffs, biomarker testing, and MRO processes.
The comment period is now live: Employers and industry groups can submit feedback or concerns via the Regulations.gov docket DOT-OST-2025-0049 until October 17, 2025.

What Employers Need to Do Now

1. Review the Proposed Rule

Take a look at the full Federal Register entry to understand specifics like cutoff levels, panel changes, and process shifts.

2. Submit Comments (If You Want to Influence Policy)

If this rule will significantly affect your operations, don’t miss the chance to provide feedback during the comment period.

3. Update Internal Compliance Planning

Even before the rule is finalized, start preparing by:

Standard 5- or 10-panel tests may not cover fentanyl at all, which is why this DOT proposal is so important. For more context, see our blog on why most workplace drug tests miss fentanyl (and what to do about it).

4. Scope Operational Impact

DOT estimates adding fentanyl could lead to ~13,000 screen positives and ~11,000 confirmations annually, with implications for onboarding, lab workflows, and SAP referrals.

5. Stay Aligned with HHS Guidelines

The proposal follows HHS changes from earlier in 2025 that added fentanyl to federal workplace testing panels. Employers should already be familiar with this shift.

Employers will also need to prepare for how fentanyl results are documented, confirmed, and managed under DOT rules. Our blog on common drug testing challenges under DOT’s Part 40 regulations explains what to expect when updating your processes.

How QuickScreen Can Help You Stay Ahead

Focus Area	QuickScreen Support
Testing Panels	Ready-to-use kits with fentanyl/norfentanyl support
Training & Policy	Collector and supervisor training; compliant policy templates
Process Updates	Guidance on eCCF updates, MRO workflows, and biomarker testing plans
Regulatory Tracking	Monitoring for comment deadlines, rule changes, and effective dates

TL; DR Snapshot

Action	Why It’s Important
Review the NPRM now	Understand upcoming cutoffs/panel changes
Comment by Oct 17, 2025	Influence the final rule based on real-world needs
Prepare internally	Update panels, policies, and training ahead of implementation
Lean on QuickScreen	Get expert support in compliance, training, and testing readiness

This proposed rule signals a critical shift in DOT drug testing. QuickScreen is here to help you navigate it from early preparations to seamless implementation.